Literature DB >> 17916047

Adjuvants in vaccines and for immunisation: current trends.

Pieranna Chiarella1, Emanuela Massi, Mariangela De Robertis, Emanuela Signori, Vito Michele Fazio.   

Abstract

Vaccines represent one of the most successful strategies in medical science. From the mechanistic perspective, vaccination works by manipulating the immune response through selecting, activating and expanding the memory of B and T cells. To determine the magnitude and quality of immune response, suitable vaccine adjuvants are required; therefore, much effort is going into finding new, effective and non-toxic adjuvant formulations focussed on the activation of key immune targets for inducing a long-term, potent and safe immune response. Significant research is being done in this area, to develop new classes of vaccines for use not only against infectious diseases, but also in the treatment of autoimmune disorders, allergies, chronic inflammatory diseases and cancer. Here the authors review and classify some of the main vaccine adjuvants on the basis of their immunomodulating properties on the immune system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916047     DOI: 10.1517/14712598.7.10.1551

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  4 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.

Authors:  Kaustabh K Maiti; Michael Decastro; Abu-Baker M Abdel-Aal El-Sayed; Matthew I Foote; Margreet A Wolfert; Geert-Jan Boons
Journal:  European J Org Chem       Date:  2010-01-01

Review 3.  Escherichia coli cytotoxic necrotizing factor 1 (CNF1): toxin biology, in vivo applications and therapeutic potential.

Authors:  Alessia Fabbri; Sara Travaglione; Carla Fiorentini
Journal:  Toxins (Basel)       Date:  2010-02-23       Impact factor: 4.546

4.  Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

Authors:  Mallesh Beesu; Subbalakshmi S Malladi; Lauren M Fox; Cassandra D Jones; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2014-08-20       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.